This "Specialty Testing" webinar describes a new serum test for bile acid malabsorption. Descriptions illustrate how the test can be used as a screening test and as a tool for therapeutic action.

By MCL Education • March 10, 2023

As someone affected by chronic liver disease, Susan Parrott knows how it feels to live in uncertainty. But every few months, the anxiety and doubt that shadow her life fade when Mayo Clinic Laboratories test results confirm her condition is in check and she can continue living life on her own terms.

By Robin Huiras-Carlson • March 6, 2023

Mayo Clinic Laboratories is committed to innovation that provides the right test at the right time for the right patients. That effort always starts with identifying gaps in patient care. Filling those gaps sometimes involves not developing new tests but finding ways to make existing tests more efficient and easier for patients.

By Barbara J. Toman • January 11, 2023

For Billy Dowell Jr., a competitive golfer, focus, determination, and course correction are essential to excelling at the sport. These skills, along with routine follow-up care and testing, are also important to navigating a life impacted by multiple chronic autoimmune conditions.

By Robin Huiras-Carlson • January 9, 2023

In this month's "Hot Topic," Melissa Snyder, Ph.D., co-director of the antibody immunology laboratory at Mayo Clinic, discusses celiac disease and the role of diagnostic testing algorithms.

By MCL Education • December 5, 2022

Puanani Hopson, D.O., explains how Mayo Clinic Laboratories’ malabsorption panel can provide timelier diagnosis for children with chronic diarrhea or unexplained weight loss. The novel panel, which bundles four existing tests, requires just one stool sample.

By Barbara J. Toman • November 15, 2022

Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.

By Barbara J. Toman • September 13, 2022

For a young child diagnosed with inflammatory bowel disease, an unexpected turn of events led by results of a Mayo Clinic Laboratories test freed him and his family from the bonds of frequent medical visits and expensive treatment, and opened the door to a life unencumbered by illness.

By Robin Huiras-Carlson • May 2, 2022

In this test specific episode of the  "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.

By Barbara J. Toman • April 19, 2022

Ann Moyer, M.D., Ph.D., discusses TPNUQ, Mayo Clinic Laboratories' genotyping test for identifying patients at risk for thiopurine toxicity. Used prior to therapy initiation, our assay evaluates for nuances in both TPMT and NUDT15, which have associations to thiopurine metabolization.

By Barbara J. Toman • April 5, 2022

In this month's "Hot Topic," Alicia Algeciras, Ph.D., DABCC, and Joshua Bornhorst, Ph.D., DABCC, discuss Alzheimer's disease CSF biomarkers.

By MCL Education • February 7, 2022

Director of Mayo Clinic’s Infectious Diseases Serology Laboratory, Elitza Theel, Ph.D., joins a discussion about COVID-19 antibody testing in a recent story on NPR.

By Tracy Will • September 22, 2021

Pua Hopson, D.O., discusses Mayo Clinic Labs’ new disaccharidase activity panel, which measures levels of five digestive enzymes to identify deficiencies that cause carbohydrate maldigestion and can lead to chronic conditions like celiac disease or inflammatory bowel disease. Performed on tissue sample biopsies during upper endoscopy, the activity panel is the gold standard test for detecting disaccharidase deficiencies.

By Samantha Rossi • June 29, 2021